AMPH vs. VKTX, TGTX, ACAD, CYTK, AKRO, KRYS, ADMA, AAPG, LNTH, and ACLX
Should you be buying Amphastar Pharmaceuticals stock or one of its competitors? The main competitors of Amphastar Pharmaceuticals include Viking Therapeutics (VKTX), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Cytokinetics (CYTK), Akero Therapeutics (AKRO), Krystal Biotech (KRYS), ADMA Biologics (ADMA), Ascentage Pharma Group International (AAPG), Lantheus (LNTH), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry.
Amphastar Pharmaceuticals vs. Its Competitors
Amphastar Pharmaceuticals (NASDAQ:AMPH) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.
Amphastar Pharmaceuticals has a net margin of 18.64% compared to Viking Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 20.76% beat Viking Therapeutics' return on equity.
Amphastar Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amphastar Pharmaceuticals has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.
65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 27.5% of Amphastar Pharmaceuticals shares are held by insiders. Comparatively, 4.1% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Amphastar Pharmaceuticals presently has a consensus target price of $31.50, suggesting a potential upside of 4.27%. Viking Therapeutics has a consensus target price of $86.92, suggesting a potential upside of 116.01%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Amphastar Pharmaceuticals.
In the previous week, Amphastar Pharmaceuticals had 20 more articles in the media than Viking Therapeutics. MarketBeat recorded 28 mentions for Amphastar Pharmaceuticals and 8 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 1.16 beat Amphastar Pharmaceuticals' score of 0.54 indicating that Viking Therapeutics is being referred to more favorably in the news media.
Summary
Amphastar Pharmaceuticals beats Viking Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Amphastar Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amphastar Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AMPH) was last updated on 8/14/2025 by MarketBeat.com Staff
MarketBeat All Access